(UKPDS 33). Lancet 352:837–853, 1998 6. UK Prospective Diabetes Study Group: U.K. Prospective Diabetes Study 28: arandomized trial of efﬁcacy of early addi-tion of metformin in sulfonylurea-treatedtype 2 diabetes. Diabetes Care 21:87–92, 1998 7. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K,Kim D, Aisporna M, Wang Y, Baron AD:Synthetic exendin-4 (exenatide) signiﬁ-cantly reduces postprandial and fastingplasma glucose in subjects with type 2 di-abetes. J Clin Endocrinol Metab 88:3082– 3089, 2003 8. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD:Effect on glycemic control of exenatide(synthetic exendin-4) additive to existingmetformin and/or sulfonylurea treatmentin patients with type 2 diabetes. Diabetes Care 26:2370–2377, 2003 9. Nielsen LL, Baron AD: Pharmacology of exenatide (synthetic exendin-4) for thetreatment of type 2 diabetes. Curr Opinion Invest Drugs 4:401–405, 2003 10. Young AA, Gedulin BR, Bhavsar S, Bodkin